Shattuck Labs, Inc. develops cancer and autoimmune disease treatments in the United States. Their primary product candidate, SL-172154 is currently being tested in Phase 1 clinical trials to treat ovarian, fallopian tube, and peritoneal cancers. They also have a second product candidate, SL-279252, in Phase 1 clinical trials to treat advanced solid tumors and lymphoma.